thought manag meet maintain outperform
way win best-in-class initi outperform
tough comp continu even tougher decemb
mitapivat one-trick poni deliv poc thalassemia
earli data suggest solid pk profil reiter
pivot karmma studi meet expect mani egg
highlight meet manag
updat aitl data inform registr path
updat set stage nccn guidelin
analyst certif import disclosur see
round turn clinic proof concept
sale nxp close
updat financi model price
updat estim providien deal contribut mix
thought manag meet maintain outperform
manag emphas robust franchis model abil outperform choppi environ revpar
environ remain soft particularli limit servic improv everi month sinc septemb capit alloc
front wh remain commit dividend growth increas opportunist brand acquisit la
americinn share repurchas particularli valuat level ebitda discount newli
appoint cfo allen deep experi wyndham maintain current capit alloc polici reflect
softer revpar environ headwind relat recent agreement lower ebitda
estim assum organ revpar/ebitda growth vs previous long-term revpar/
ebitda guidanc maintain outperform
manag present pipelin updat includ preliminari process-b data demonstr earli
engraft signal clinic stabil two fanconi anemia-a fa-a patient posit data
two leukocyt adhes patient updat safeti signal seen two danon
diseas patient treat pipelin demonstr increas clinic valid feel increasingli
confid could pivot year manag matur pipelin multipl potenti registr enabl
trial rais price target increas assumpt probabl success
reiter outperform thesi
way win best-in-class initi outperform
initi coverag inc outperform pt base view differenti
approach nonalcohol steatohepat nash sever hypertriglyceridemia shtg novel mechan action
moa promis earli clinic data low compar valuat lead asset develop
nash shtg two larg area unmet medic need long-act glycopegyl fibroblast growth factor
analog engin use proprietari technolog prolong biolog activ nativ believ
potenti becom foundat nash shtg therapi best-in-class among analog
estim peak sale nash shtg detail full report publish
tough comp continu even tougher decemb
novemb monthli data show overal industri averag daili trade volum adv still yoy major
asset class except agricultur commod metal good news adv rose mom indic
octob report expect comp get easier least despit adv expect yoy
open interest mani asset class still indic potenti higher futur trade volum expect exchang
somewhat pressur given lack volatil far believ share price yet
get calm period back normal comp could look back realiz present good
buy opportun exchang investor medium- long-term invest horizon continu recommend
mitapivat one-trick poni deliv poc thalassemia
sunday agio announc proof-of-concept data mitapivat first-in-class oral activ pyruv kinase-r pkr
non-transfus depend thalassemia non-tdt result show convinc benefit evalu patient
achiev hemoglobin increas g/dl baselin believ data point broader util mitapivat
beyond pyruv kinas defici pkd could spur agio expand develop effort includ rang chronic
anemia critic near-term catalyst includ dual pivot trial readout activ activate-t pyruv kinas
defici pkd expect view aggress develop plan mitapivat could help agio recov stall
momentum slow tibsovo sale lukewarm earli data reiter perform
earli data suggest solid pk profil reiter outperform
saturday aptos held investor event focus select non-coval inhibitor featur
commentari renown kol brian druker oregon scienc univers compani provid updat
first two b-cell malign patient treat on-going phase encourag pk profil
show clear dose-depend chang exposur earli sign clinic activ second treat patient
far well toler shown sign myelosuppress view critic drug
potenti aml dose escal on-going mg bid compani plan open test aml patient earli
pivot karmma studi meet expect mani egg bcma nest
friday bluebird bio bristol-my squibb bm announc highly-anticip pivot result karmma trial
ide-cel believ data larg in-lin prior result trial provid
strong support bla file relapsed/refractori multipl myeloma slate critic may point fewer complet
respons lower mpf rel publish phase result manag confirm karmma enrol
refractori popul rel studi investor event sunday bm manag emphas vision
deploy differ bcma-target therapi car-t t-cell engag depend patient circumst
anticip fda approv late investor may need reset sale expect first-in-class product reiter
friday held investor event review recent clinic progress pipelin develop event includ
surpris clinic vignett first aml patient treat appear track toward complet
remiss howev solid tumor remain tough nut crack object respons observ first
patient treat compani propos sever protocol modif aim boost activ although
program remain potenti upsid thesi believ could transform year import
data key value-driv program aml nhl respect reiter outperform pt
highlight meet manag
sat manag meet orlando discuss next step global blood follow oxbryta
recent fda approv formulari review underway expect see meaning sale revenu begin
sever poster present strengthen case use oxbryta broad cross-sect sickl cell patient
post-hoc analys showcas drug safeti compat standard-of-car hydroxyurea hu
note oral present highlight preclin hemoglobin modifi properti reminisc
oxbryta caught dr martin steinberg sickl cell diseas kol pleas approv see
oxbryta deploy case hu inadequ resolv symptom reiter outperform pt
updat aitl data inform registr path
announc updat data tipifarnib r/r aitl/ptcl heavili pre-treat patient
data cutoff orr pp five five pr median durat
respons design test higher orr base express significantli
lower aitl tumor carri variant potenti resist pathway tipifarnib
observ orr aitl subgroup plan initi registr trial includ
primari endpoint orr variant patient slightli delay forecast launch time increas po
maintain pt detail full report date
updat set stage nccn guidelin
updat retrospect analysi studi compar momelotinib ruxolitinib myelofibrosi mf
signific consist anemia benefit momelotinib could set stage eventu first line treatment posit
nccn guidelin opinion hand srra current momentum studi compar momelotinib danazol
recommend nccn guidelin approv mf treatment second line set view data
present seem support futur nccn inclus if/when momelotinib approv reinforc thesi
momelotinib signific commerci opportun patient anemia irregardless line treatment prior jak
exposur reiter outperform thesi pt report detail
round turn clinic proof concept
attend american societi hematolog decemb compendium clinic updat
cll treatment landscap present sunesi poster phase progress
vecabrutinib demonstr trend clinic activ favor toler set stage futur updat initi
efficaci cohort like competit agent reversible-btk class matur expect greater
attent paid regulatori strategi path-to-market could greater point differenti initi
rate efficaci snss near potenti inflect updat phase program stay bullish
sale nxp close
marvel close sale connect busi nxp friday updat jan sale guidanc
adjust estim accur reflect divestitur sales/ep forecast increas
estim unchang respect exclud out-year
contribut follow tuesday oct earn link sale complet three deal announc may
aq acquisit multi-gig phi acquisit avera custom asic sale non-cor
connect like streamlin move strategic/accret management paid sale aq/avera combin run-
rate revenu sold sale believ proven management team chop deliv upsid refocus
top-line top growth stori remain buyer
snapdragon flagship fabric tsmc without euv digitim
mark papermast core come slow moor law ee time
impinj releas new rain rfid tag chip retail suppli chain applic everyth rf
updat financi model price
updat financi model reflect latest think fulli incorpor margin
pressur follow compani report late novemb believ street project still tad aggress
closer realiti view tariff remain potenti wildcard upsid downsid go forward follow
recent share price declin see meaning downsid risk share remain attract valu
ebitda gap dg remain key attract us dg continu repres prefer play
updat estim providien deal contribut mix rate segment dynam
revis model close csl providien acquisit meaning expand med-tech presenc earli
start winter partli offset solid ccm trend on-going cyclic headwind cft cbf adjust
slightli lower ep outlook remain confid oper trajectori key ccm
platform account revenu ebit posit strong profit growth beyond
continu like risk/reward given discount valuat includ near coverage-high yield outsiz earn
cash flow trajectori visibl pathway run rate ep establish solid foundation/
momentum toward ep contempl vision
last week us court intern trade announc allow exclus bifaci modul section
tariff given lack suffici notic reason us trade repres ustr ustr yet
respond expect respons come week time potenti impact on-going trade negoti
us china exclus place would see biggest impact group import
bifaci modul repres meaning competitor product expect unresolv appeal process cast
doubt fulli load bifaci modul price like limit impact contract negoti moment
remain sidelin given view even tariff place bifaci modul like pressur
price earn power time
may biotech summit featur chemistri life process institutechicago
